JP6029591B2 - ナノポリマーをベースとした核酸送達のための組成物および方法 - Google Patents

ナノポリマーをベースとした核酸送達のための組成物および方法 Download PDF

Info

Publication number
JP6029591B2
JP6029591B2 JP2013537902A JP2013537902A JP6029591B2 JP 6029591 B2 JP6029591 B2 JP 6029591B2 JP 2013537902 A JP2013537902 A JP 2013537902A JP 2013537902 A JP2013537902 A JP 2013537902A JP 6029591 B2 JP6029591 B2 JP 6029591B2
Authority
JP
Japan
Prior art keywords
poly
nucleic acid
acetylglucosamine
composition
deacetylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013537902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500250A5 (enExample
JP2014500250A (ja
Inventor
ヴールナキス，ジョン，エヌ．
デムシェヴァ，マリナ，ヴィ．
Original Assignee
マリン ポリマー テクノロジーズ，インコーポレーテッド
マリン ポリマー テクノロジーズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マリン ポリマー テクノロジーズ，インコーポレーテッド, マリン ポリマー テクノロジーズ，インコーポレーテッド filed Critical マリン ポリマー テクノロジーズ，インコーポレーテッド
Publication of JP2014500250A publication Critical patent/JP2014500250A/ja
Publication of JP2014500250A5 publication Critical patent/JP2014500250A5/ja
Application granted granted Critical
Publication of JP6029591B2 publication Critical patent/JP6029591B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2013537902A 2010-11-06 2011-11-07 ナノポリマーをベースとした核酸送達のための組成物および方法 Expired - Fee Related JP6029591B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41086310P 2010-11-06 2010-11-06
US61/410,863 2010-11-06
US41135810P 2010-11-08 2010-11-08
US61/411,358 2010-11-08
PCT/US2011/059558 WO2012061803A2 (en) 2010-11-06 2011-11-07 Compositions and methods for nanopolymer-based nucleic acid delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016080377A Division JP2016164181A (ja) 2010-11-06 2016-04-13 ナノポリマーをベースとした核酸送達のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2014500250A JP2014500250A (ja) 2014-01-09
JP2014500250A5 JP2014500250A5 (enExample) 2015-02-05
JP6029591B2 true JP6029591B2 (ja) 2016-11-24

Family

ID=46025153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013537902A Expired - Fee Related JP6029591B2 (ja) 2010-11-06 2011-11-07 ナノポリマーをベースとした核酸送達のための組成物および方法
JP2016080377A Pending JP2016164181A (ja) 2010-11-06 2016-04-13 ナノポリマーをベースとした核酸送達のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016080377A Pending JP2016164181A (ja) 2010-11-06 2016-04-13 ナノポリマーをベースとした核酸送達のための組成物および方法

Country Status (10)

Country Link
US (3) US20130287853A1 (enExample)
EP (1) EP2635261B1 (enExample)
JP (2) JP6029591B2 (enExample)
CN (2) CN103282024A (enExample)
AU (3) AU2011323078B2 (enExample)
CA (1) CA2816999A1 (enExample)
ES (1) ES2763432T3 (enExample)
IL (1) IL226170B (enExample)
MX (1) MX358050B (enExample)
WO (1) WO2012061803A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016164181A (ja) * 2010-11-06 2016-09-08 マリン ポリマー テクノロジーズ，インコーポレーテッド ナノポリマーをベースとした核酸送達のための組成物および方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
CA2796068C (en) 2010-04-15 2022-07-19 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly-n-acetylglucosamine nanofibers
MX356877B (es) 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
CA2968160C (en) * 2016-05-31 2024-01-02 Sachiko Sato Use of n-acetylglucosamine and derivatives thereof to treat muscle disorders
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
IT202200004574A1 (it) * 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB0126923D0 (en) * 2001-11-09 2002-01-02 Procter & Gamble Chitosan compositions
US7780873B2 (en) * 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
JP2005281239A (ja) * 2004-03-30 2005-10-13 Nippon Zeon Co Ltd 鶏用ｄｎａワクチン
CA2487564A1 (en) * 2004-11-12 2006-05-12 Valorisation Recherche Hscm Folic acid-chitosan-dna nanoparticles
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2068917A2 (en) * 2006-09-22 2009-06-17 Government of the USA, as Represented by the Secretary, Department of Health and Human Services Compositions and methods for chitosan enhanced immune response
KR100882611B1 (ko) * 2006-11-14 2009-02-12 주식회사 키토라이프 표적 리간드로서 폴릭산이 도입된 유전자 전달체용저분자량 수용성 키토산 나노입자 및 이의 제조방법
KR20090108723A (ko) * 2007-01-31 2009-10-16 알러간, 인코포레이티드 안 약물 송달을 위한 신규한 생체적합물질 및 이의 제조방법 및 용도
US20100086613A1 (en) * 2008-10-03 2010-04-08 Chang-Jer Wu Chitosan vehicle and method for making same
US20100105139A1 (en) * 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
CA2833415A1 (en) * 2010-05-10 2011-11-17 Corporation De L'ecole Polytechnique De Montreal Gene therapy for diabetes with chitosan-delivered plasmid encoding glucagon-like peptide 1
EP2635261B1 (en) * 2010-11-06 2019-10-23 Marine Polymer Technologies, Inc. Compositions and methods for nanopolymer-based nucleic acid delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016164181A (ja) * 2010-11-06 2016-09-08 マリン ポリマー テクノロジーズ，インコーポレーテッド ナノポリマーをベースとした核酸送達のための組成物および方法

Also Published As

Publication number Publication date
AU2016201640A1 (en) 2016-04-07
ES2763432T3 (es) 2020-05-28
AU2011323078B2 (en) 2016-04-14
CN108743562A (zh) 2018-11-06
AU2011323078A1 (en) 2013-05-02
WO2012061803A3 (en) 2012-08-16
EP2635261A2 (en) 2013-09-11
US20170128382A1 (en) 2017-05-11
US20130287853A1 (en) 2013-10-31
IL226170A0 (en) 2013-07-31
US20230157971A1 (en) 2023-05-25
CA2816999A1 (en) 2012-05-10
EP2635261A4 (en) 2014-09-17
MX358050B (es) 2018-08-03
JP2016164181A (ja) 2016-09-08
AU2013203247A1 (en) 2013-05-09
MX2013005016A (es) 2014-03-12
JP2014500250A (ja) 2014-01-09
CN103282024A (zh) 2013-09-04
EP2635261B1 (en) 2019-10-23
IL226170B (en) 2018-11-29
WO2012061803A2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
US20230157971A1 (en) Compositions and methods for nanopolymer-based nucleic acid delivery
US20220023204A1 (en) Biologically active dry powder compositions and method of their manufacture and use
JP6827488B2 (ja) 鼻内送達のための方法および組成物
Zhao et al. Enhancing mucosal immune response of Newcastle disease virus DNA vaccine using N-2-hydroxypropyl trimethylammonium chloride chitosan and N, O-carboxymethyl chitosan nanoparticles as delivery carrier
ES2791152T3 (es) Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
US8492142B2 (en) Freeze-dried product for introducing nucleic acid, oligonucleic acid or derivative thereof
JP5923177B2 (ja) 新規な遺伝子伝達用組成物
Wang et al. Advances of nanotechnology toward vaccine development against animal infectious diseases
US20220145309A1 (en) Yeast-Based Oral Vaccination
US20250195642A1 (en) Nucleic acid stabilizing solution for vaccines, therapy, diagnostics, storage, and transport
AU755126B2 (en) Stable gene preparations
Hussain et al. Nanoparticle-Mediated Mucosal Vaccination: Harnessing Nucleic Acids for Immune Enhancement: Nanoparticle-Mediated Mucosal Vaccination
WO2020099869A1 (en) Nanoparticles and uses thereof
TW202302141A (zh) 生物可降解的奈米複合疫苗、核糖核酸及去氧核糖核酸疫苗之方法
WO2024128201A1 (ja) ｍＲＮＡワクチン
WO2025166259A1 (en) Mineral binding mrna lipid nanoparticles
Heuking et al. Pulmonary Delivery of Plasmid DNA for Disease Prevention and Therapy

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151013

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161018

R150 Certificate of patent or registration of utility model

Ref document number: 6029591

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees